Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 83103776 | 8310377 | 6 | F | 201111 | 20160729 | 20111223 | 20160803 | EXP | GB-PFIZER INC-2011308637 | PFIZER | 32.00 | YR | M | Y | 61.00000 | KG | 20160803 | MD | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 83103776 | 8310377 | 1 | PS | VANCOMYCIN | VANCOMYCIN | 1 | Intravenous (not otherwise specified) | 1000 MG, 2X/DAY | Y | 11I26VM01 | 62911 | 1000 | MG | BID | |||||
| 83103776 | 8310377 | 2 | SS | KEPPRA | LEVETIRACETAM | 1 | 250 MG, 2X/DAY | Y | 0 | 250 | MG | BID | |||||||
| 83103776 | 8310377 | 3 | SS | EPILIM | VALPROATE SODIUM | 1 | Intravenous (not otherwise specified) | 300 MG, 2X/DAY | Y | 0 | 300 | MG | BID | ||||||
| 83103776 | 8310377 | 4 | C | ALFENTANIL. | ALFENTANIL | 1 | UNK | 0 | |||||||||||
| 83103776 | 8310377 | 5 | C | CHLORHEXIDINE | CHLORHEXIDINE | 1 | UNK | 0 | |||||||||||
| 83103776 | 8310377 | 6 | C | DOCUSATE | DOCUSATE | 1 | UNK | 0 | |||||||||||
| 83103776 | 8310377 | 7 | C | FRUSEMIDE | FUROSEMIDE | 1 | UNK | 0 | |||||||||||
| 83103776 | 8310377 | 8 | C | MAGNESIUM | MAGNESIUM | 1 | UNK | 0 | |||||||||||
| 83103776 | 8310377 | 9 | C | MAGNESIUM SULFATE. | MAGNESIUM SULFATE | 1 | UNK | 0 | |||||||||||
| 83103776 | 8310377 | 10 | C | METOCLOPRAMIDE. | METOCLOPRAMIDE | 1 | UNK | 0 | |||||||||||
| 83103776 | 8310377 | 11 | C | MIDAZOLAM | MIDAZOLAMMIDAZOLAM HYDROCHLORIDE | 1 | UNK | 0 | |||||||||||
| 83103776 | 8310377 | 12 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | UNK | 0 | |||||||||||
| 83103776 | 8310377 | 13 | C | PABRINEX | 2 | UNK | 0 | ||||||||||||
| 83103776 | 8310377 | 14 | C | PROPOFOL. | PROPOFOL | 1 | UNK | 0 | |||||||||||
| 83103776 | 8310377 | 15 | C | SENNA | SENNA LEAFSENNOSIDESSENNOSIDES A AND B | 1 | UNK | 0 | |||||||||||
| 83103776 | 8310377 | 16 | C | BETAINE/POLYHEXANIDE | 2 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 83103776 | 8310377 | 2 | Seizure |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 83103776 | 8310377 | OT |
| 83103776 | 8310377 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 83103776 | 8310377 | Drug reaction with eosinophilia and systemic symptoms | |
| 83103776 | 8310377 | Eosinophilia | |
| 83103776 | 8310377 | Hepatitis | |
| 83103776 | 8310377 | Neutropenia | |
| 83103776 | 8310377 | Neutrophilia | |
| 83103776 | 8310377 | Rash erythematous | |
| 83103776 | 8310377 | Renal impairment | |
| 83103776 | 8310377 | Transaminases increased | |
| 83103776 | 8310377 | Tubulointerstitial nephritis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 83103776 | 8310377 | 1 | 201111 | 20111107 | 0 | |
| 83103776 | 8310377 | 2 | 20111103 | 20111103 | 0 | |
| 83103776 | 8310377 | 3 | 20111031 | 20111103 | 0 |